重新审视AJCC第八版T2b与T3非小细胞肺癌分期分类
本研究基于美国国家癌症数据库(2010-2015)31,563例T2b-T3、N0-3、M0非小细胞肺癌患者,采用多因素Cox模型和倾向评分匹配,外部验证IASLC分期项目结果。发现同叶附加结节(T3-Add)的总生存优于T3-Size(HR=0.86,95%CI 0.82-0.89,p<0.001),与T2b相似(HR=1.04,95%CI 0.97-1.12,p=0.28);倾向评分匹配后5年生存率53.4%对52.3%(p=0.30)。提示T3-Add或可考虑用于AJCC第九版分期修订。
要点
- T3-Add(同叶附加结节)总生存优于T3-Size(HR=0.86,95%CI 0.82-0.89,p<0.001)。
- T3-Add与T2b总生存相似(HR=1.04,95%CI 0.97-1.12,p=0.28)。
- 倾向评分匹配后T3-Add与T2b的5年生存率分别为53.4%和52.3%(p=0.30)。
核心结论
- 在本全国性分析中,T3-Add肿瘤的生存优于其他T3肿瘤,与T2b肿瘤相似。
- 这些发现或可考虑用于AJCC第九版分期分类。
研究设计与样本
- 基于美国国家癌症数据库(2010-2015)的回顾性队列研究。
- 纳入31,563例T2b-T3、N0-3、M0非小细胞肺癌患者,满足单一T描述符:T2b(>4cm但≤5cm)、T3-Size(>5cm但≤7cm)或T3-Add(同叶附加结节)。
- 采用多因素Cox比例风险模型和倾向评分匹配进行分析。
主要发现
- 多因素调整分析中,T3-Add总生存优于T3-Size(HR=0.86,95%CI 0.82-0.89,p<0.001)。
- T3-Add与T2b总生存相似(HR=1.04,95%CI 0.97-1.12,p=0.28)。
- 倾向评分匹配分析纳入2260例T3-Add和2260例T2b患者,16个常见预后协变量(包括治疗类型:手术、化疗或放疗)均衡良好。
- 匹配后T3-Add与T2b的5年生存率分别为53.4%和52.3%(p=0.30)。
临床怎么用
- 对于同叶附加结节的NSCLC,其生存预后与T2b相似而非其他T3,临床分期评估时可参考此结果。
- 该发现可为AJCC第九版分期修订提供外部验证依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The American Joint Committee on Cancer (AJCC) eighth edition TNM staging manual for NSCLC, derived from the International Association for the Study of Lung Cancer (IASLC) Staging Project, designates tumors with additional nodule(s) in the same lobe as T3. This study sought to externally validate the results of the IASLC, which showed a trend in improved survival for such tumors, but excluded treatment-based adjustment, by assessing whether these tumors have worse survival than T2b NSCLC. METHODS: Overall survival of patients with T2b-T3, N0-3, M0 NSCLC (satisfying a single T descriptor of tumors >4 cm but ≤5 cm in greatest dimension ["T2b"], tumors >5 cm but ≤7 cm in greatest dimension ["T3-Size"], or tumors with additional nodule(s) in the same lobe ["T3-Add"]), according to the AJCC eighth edition, in the National Cancer Database (2010-2015), was evaluated using multivariable Cox proportional hazards modeling and propensity score matching. RESULTS: 31,563 patients with T2b-T3, N0-3, M0 NSCLC met the study inclusion criteria. In multivariable-adjusted analysis, T3-Add tumors had improved overall survival compared with T3-Size tumors (Hazard Ratio = 0.86, 95% Confidence Interval: 0.82-0.89, p < 0.001) and similar survival compared with T2b tumors (Hazard Ratio = 1.04, 95% Confidence Interval: 0.97-1.12, p = 0.28). A propensity score-matched analysis of 2260 T3-Add and 2,260 T2b patients, well-balanced on 16 common prognostic covariates, including treatment type (surgery, chemotherapy, or radiation), revealed similar 5-year survival (53.4% versus 52.3%, p = 0.30). CONCLUSIONS: In this national analysis, T3-Add tumors had better survival than other T3 tumors and similar survival to T2b tumors. These findings may be taken into consideration for the AJCC ninth edition staging classifications.
引用
- Kumar A, Kumar S, Gilja S, et al. Reconsidering the American Joint Committee on Cancer Eighth Edition TNM Staging Manual Classifications for T2b and T3 NSCLC. J Thorac Oncol. 2021. PMID: 34242788. doi:10.1016/j.jtho.2021.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。